Medpace Holdings Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: Medpace Holdings Inc is far larger — about 4.6× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| MEDP | ZIM | |
|---|---|---|
Market Cap | $16.82B | $3.65B |
Volume | 223,093 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $630.19 | $30.51 |
52-Week Low | $393.42 | $12.44 |
Typical Hold Time | 14 Days | 27 Days |
Enterprise Value | $16.44B | $7.32B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
ZIM Integrated Shipping Services trades at $30.26, up 0.9% today and near its 52-week high of $30.96. The stock shows bullish technical momentum with strong moving average signals, though RSI indicators suggest potential overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with $0.53 EPS versus -$0.02 expected, driven by 9% revenue growth to $1.8 billion. The company faces acquisition uncertainty with Hapag-Lloyd's $35 per share offer pending Israeli government approval.
Investment outlook remains mixed with strong operational performance offset by merger uncertainty. The stock trades at attractive valuations (P/S 0.57, P/B 0.94) but faces headwinds from declining 2026 profit margins (2.15% vs 6.94% in 2025). Analyst consensus leans cautious with 67% hold ratings, while technical indicators suggest near-term resistance at current levels. Key risks include government approval of acquisition and volatile shipping rates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →